Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant.
After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he led KPMG’s involvement in the IPO of the medical technology company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG’s UK and European High Technology Practices and High Technology Consulting Group. Andrew founded ANGLE in 1994. Together with ANGLE’s senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.
NA Vice President
Peggy Robinson is leading relationships with US key opinion leaders and responsible for US sales and corporate deals with major pharmaceutical and medtech companies. Prior to joining ANGLE, Peggy was the principal of BioMark Consulting, LLC, a boutique consulting firm focused on business strategies, marketing, strategic alliances, KOL and product development of new technologies, with an emphasis on cancer diagnostics, chronic diseases and companion diagnostics.
In prior experience, Peggy was director of marketing for Veridex, a Johnson & Johnson company, and its predecessor Immunicon, responsible for the launch and market expansion of CellSearch® research products and services. Additionally, in 2011 and 2012, Peggy was Director of Strategic Alliances / Services for Veridex. During this time she developed and implemented strategies to form collaborations for CellSearch with pharmaceutical and biotech companies. Additional experience includes serving as Director of Systems Biology Market Development at EMD Millipore (a division of Merck Group) and as the Head of Global Marketing Communications with Siemens Medical Solutions Diagnostics, where she managed the Marketing Communications Department for the Diagnostics Division. Complementing her comprehensive marketing expertise includes a strong clinical background as a medical technologist. Her educational background and professional credentials include a Bachelor’s degree in Biology / Medical Technology and registration as a Medical Technologist. She currently serves as the president of the Diagnostics Marketing Association (DxMA) and was awarded the Jerry R Goldsmith Award for marketing excellence, by leaders in the industry.
Chief Technology Officer
Jay joined ANGLE in 2017 with over thirty years of experience in Life Science / Medical product development, covering multi-partner collaborations, technology acquisition, IP management, project management, quality systems (ISO9001, ISO13485), clinical trials, business development and successful technology commercialisation in international markets.
Jay’s main expertise is the simplification and commercialisation of complex biological systems for use by non-technical operators in non-laboratory environments. He has led several projects developing products for automated water toxicity monitoring, detection of airborne microbial and chemical contamination, farm-based instruments for diagnosis of veterinary diseases and Point of Care medical devices for the rapid diagnosis and treatment of infections. Jay is a microbiologist with a Ph.D. in microbial genetics and a research background in the genetic regulation of complex metabolic pathways related to pesticide degradation and the development of antimicrobial resistance. He has held various technical positions in large FTSE 100 (Amersham International, Merck Group, Smiths Detection) and SME start-up companies (AZUR Environmental, Enigma Diagnostics, Immunexpress), working in UK, Germany and USA. During his time with Smiths Detection, Jay was responsible for the development of the business case and acquisition of the technology which established a new business unit to develop products for veterinary & clinical diagnostics, securing government and private venture investment, and resulting in a marketing & licensing agreement with a major pharmaceutical company, providing route to market for human IVD products and R&D milestone income. Most recently Jay was CTO of Immunexpress where he led the translation of a genetic test for inflammation (sepsis) from a manual laboratory test to an automated ‘STAT lab’ platform.
US Chief Technology Officer Microfluidics
George E. Hvichia, PhD, inventor of the Parsortix technology, and Vice President of Research was trained in Bioengineering and is an expert in Microfluidics and Biochips. He has developed microdevices for industry and in academic settings.
Dr. Hvichia is the author of several peer-reviewed publications on microdevices, currently holds two US patents in field of Diagnostic Microstructures and has several more patents pending for the Parsortix technology.
Chief Financial Officer
Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
He joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures, both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic business Parsortix.
Business Development Director
Michael has extensive experience of commercialising new technologies, with a solid background in strategic and operational leadership. Michael joined ANGLE six years ago to lead a government backed technology incubator. The incubator evaluated more than 60 early stage technology companies from around the UK before selecting the highest potential start-ups and providing intense consultancy support in setting technology milestones, developing an effective business model, building collaborations and securing early customers.
The technology incubator helped companies to raise in excess of £45m private investment and also put in place a number of corporate relationships to fast-track technology to market. Prior to ANGLE, Michael gained eight years leadership experience, as Strategy and Operations director of a media company, during which time he led its merger with a sister company to form and then launch a new £4.5m company known as RadioCentre. During this time Michael chaired a number of highly successful cross industry collaboration projects. Michael’s early career was spent at Diageo within the Corporate Strategy department where he focused on manufacturing and technology strategy, both in the UK and in operational business units in Indonesia, Australia and Singapore. Michael has an MA in Engineering Science from the University of Cambridge and an MBA from the University of Warwick, specialising in technology commercialisation.
Director of Operations & Regulatory Affairs
Martin is the Head of Manufacturing and Regulatory at Parsortix, a Chartered Engineer and holds an MEng degree in Electrical and Electronic Engineering from The University of Nottingham. He joined ANGLE in 2004 and specialises in technology commercialisation and knowledge transfer projects supporting businesses, particularly involving universities and other specialist knowledge and research centres.
Martin’s early career was spent as a practicing design engineer in the military, instrumentation and telecommunications sectors with particular experience in high-precision analogue measurement techniques, intrinsic safety and embedded systems. Having progressed through a number of senior technical and commercial positions, Martin became the Product Manager of a multi-million dollar international product family at a global telecommunications equipment provider. In this role he was responsible for product concepts, new product development and market introductions, together with associated transition to stable manufacturing and supply. The role also encompassed on-going technical support for existing products and a large, established customer base.
Clinical Studies Director
Craig Miller joined ANGLE in March of 2016 as the Clinical Studies Director, where he is responsible for driving the clinical development activities of ANGLE. He has over 20 years of experience in the RUO and IVD diagnostics industry, including clinical trial management, clinical data management, biostatistics, regulatory submissions, and manuscript writing and editing (Craig is a co-author on over 80 peer-reviewed publications in the field of oncology and diagnostics).
Prior to joining ANGLE, Craig was the Vice President of Clinical Development at Saladax Biomedical, where he was responsible for the design, implementation, and execution of clinical studies for the validation of novel therapeutic drug monitoring assays (MyCare®) in the field of oncology. Before that, he was the Associate Director of Clinical Research for the Veridex Oncology Biomarkers team at Janssen R&D, a Johnson & Johnson company, where he was responsible for the design, implementation, coordination, and execution of clinical research and development trials for the evaluation, characterization, and commercialization of circulating tumor cell (CTC) assays and technologies. During his 12 year tenure with Veridex/Janssen R&D (formerly Immunicon Corporation), Craig was instrumental in obtaining de-novo FDA clearance of the CELLSEARCH® system and associated components (i.e. CELLTRACKS® AUTOPREP® and CELLTRACKS® ANALYZER® instruments, CELLSAVE preservative tube, and CELLSEARCH® CTC Kits). As the Director of Clinical Affairs and Biostatistics at Fujirebio Diagnostics, Inc., he played a key role in the clinical validation and FDA clearance of the MESOMARK® and ROMA® assays. Craig started his career in diagnostics at UroCor (now Dianon Pathology, a division of LabCorp), where he held positions of increasing responsibility in Research & Development for new and innovative products in the detection, prognosis, and monitoring of urologic diseases (primarily prostate and bladder cancer). Craig has a BS in Biochemistry from Texas A&M University.
U.S. Vice President Sales
Brad Spitz joined ANGLE in 2016 and has responsibility for sales strategies and tactics in North America. Brad is a highly accomplished life sciences executive who has diverse experience spanning the biotech, pharmaceutical, molecular diagnostics, and oncology healthcare sectors.
Prior to joining ANGLE, Brad spent 19 years at Johnson and Johnson Medical, where he most recently served as the Western Regional Sales Director with Janssen Diagnostics. Brad helped introduce CellSearch™, the first and only FDA approved technology for capturing, enumerating, and analyzing Circulating Tumor Cells (CTCs). Brad drove increased utilization of CTCs and other rare cell technologies into the biotechnology and pharmaceutical sector as well as key academic research centers, NCI institutions, oncology clinics, and hospitals across Western US and Canada. He was an active member of the senior leadership team involved in gaining product access and reimbursement, sales training, compensation planning, launching sales force automation, creating digital marketing strategy, and long term business planning. Brad has a proven track record of leading teams and delivering results. He has won numerous sales awards over his professional career at Janssen Diagnostics, Ortho-Clinical Diagnostics, Ethicon, and Advanced Wound Care. Brad received his Bachelor of Science degree from the University of Wisconsin – Madison and his MBA from ELON University in North Carolina.
Vice President; CEO ANGLE Biosciences, Inc.
Paul Smith is the CEO of ANGLE Biosciences, Inc.. Prior to joining ANGLE, Paul most recently served as President and CEO of Axela Inc. a company specializing in the development of multiplex biomarker tools. He has more than 30 years of experience in the life science instrumentation field with a diverse background in sales, marketing and field operations.
A major focus has been commercializing new technologies through collaborative partnerships with academic, pharmaceutical and industrial clients. Previously, Mr. Smith held the positions of Vice-President, Sales Europe and North America and Director, European Operations for Ciphergen Biosystems Inc., a company focused on translating proteomics-based biomarker discoveries into high value research and clinical diagnostic assays.